BRICKBIO INC.

BOSTON, MA · Founded 2019 · Biotech · Private

Bioconjugation platform enabling site-specific, site-selective modification of antibodies and proteins

Claim this profile

Follows are private to you and power your alerts

Updated · brickbio.com

Sector
Biotech
Headquarters
BOSTON, MA
Founded
2019
Latest Form D
$5M, Nov 2019
Total capital
$5M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$5M
1 Form D · last Nov 2019
83 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
12 pending

Capital timeline

2019FEDERAL ↑EQUITY ↓Cumulative $5M1st Form D$5M
2019FEDERAL ↑EQUITY ↓Cumulative $5M1st Form D$5M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$5M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Alexander RobertsonExecutive OfficerNamed in SEC Form D filings
  • Caylin NavoExecutive OfficerNamed in SEC Form D filings
  • Cheri WalkerDirectorNamed in SEC Form D filings
  • Elouise ManhertzExecutive OfficerNamed in SEC Form D filings
  • John BoyceDirectorNamed in SEC Form D filings
  • Scott ShermanExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 12
  • PendingAntibodies Containing Unnatural Amino Acids And Methods Of Making And Using The SameUSPTOApplication 18044943
  • PendingProtein Derivatives Containing Unnatural Amino Acids And Branched LinkersUSPTOApplication 18254308
  • PendingStable Cell Lines For Site-specific Incorporation Of Unnatural Amino AcidsUSPTOApplication 18040933
Show all 12 patent records
  • Antibodies Containing Unnatural Amino Acids And Methods Of Making And Using The SameSep 26, 2024 · Application 18044943Pending
  • Protein Derivatives Containing Unnatural Amino Acids And Branched LinkersJan 4, 2024 · Application 18254308Pending
  • Stable Cell Lines For Site-specific Incorporation Of Unnatural Amino AcidsOct 5, 2023 · Application 18040933Pending
  • Aminoacyl-trna Synthetases And Cell Lines For Site-specific Incorporation Of Unnatural Amino AcidsOct 13, 2022 · Application 17633672Pending
  • Stable Cell Lines For Site-specific Incorporation Of Unnatural Amino AcidsApplication 63210593Pending
  • Methods And Compositions For Analyte Detection And QuantificationApplication PCTUS2020047061Pending
  • Stable Cell Lines For Site-specific Incorporation Of Unnatural Amino AcidsApplication 63063065Pending
  • CD276 (B7-H3) Antibody-drug ConjugatesApplication PCTUS2023077689Pending
  • Aminoacyl-trna Synthetases And Cell Lines For Site-specific Incorporation Of Unnatural Amino AcidsApplication PCTUS2020045506Pending
  • Protein Derivatives Containing Unnatural Amino Acids And Branched LinkersApplication PCTUS2021060853Pending
  • Antibodies Containing Unnatural Amino Acids And Methods Of Making And Using The SameApplication PCTUS2021049953Pending
  • Stable Cell Lines For Site-specific Incorporation Of Unnatural Amino AcidsApplication PCTUS2021045088Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .